Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTCNASDAQ:HUMANASDAQ:KMDAOTCMKTS:TBUFF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTCBenitec Biopharma$15.75-4.4%$14.20$5.74▼$17.15$413.44M0.4441,998 shs87,778 shsHUMAHumacyte$2.41+1.7%$1.93$1.15▼$9.79$373.84M23.86 million shs1.53 million shsKMDAKamada$7.15+3.9%$6.68$4.74▼$9.16$411.16M0.9493,877 shs90,056 shsTBUFFTribute Pharmaceuticals Canada$0.00$0.50▼$1.86$105.76MN/A71,826 shs50,100 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTCBenitec Biopharma0.00%+3.00%+21.18%+7.43%+125.44%HUMAHumacyte0.00%-8.49%+5.80%-21.26%-66.38%KMDAKamada0.00%+0.44%-0.86%+1.18%+35.17%TBUFFTribute Pharmaceuticals Canada0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNTCBenitec Biopharma2.5036 of 5 stars3.62.00.00.03.02.50.0HUMAHumacyte2.3385 of 5 stars3.51.00.00.02.62.50.6KMDAKamada3.9245 of 5 stars3.43.00.00.03.11.73.1TBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTCBenitec Biopharma 3.22Buy$23.8351.32% UpsideHUMAHumacyte 3.00Buy$11.71386.07% UpsideKMDAKamada 2.75Moderate Buy$14.67105.13% UpsideTBUFFTribute Pharmaceuticals Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TBUFF, BNTC, HUMA, and KMDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.005/19/2025BNTCBenitec BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.005/15/2025BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.005/15/2025KMDAKamadaBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.005/14/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.005/14/2025HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $14.005/13/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/8/2025KMDAKamadaSidotiSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/10/2025BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$18.00 ➝ $20.003/26/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/24/2025BNTCBenitec BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTCBenitec Biopharma$80K5,167.97N/AN/A$3.24 per share4.86HUMAHumacyte$517K723.09N/AN/A$0.13 per share18.54KMDAKamada$167.24M2.46$0.40 per share17.90$4.25 per share1.68TBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTCBenitec Biopharma-$21.75M-$1.51N/AN/AN/AN/A-44.61%-41.25%N/AHUMAHumacyte-$110.78M-$0.69N/AN/AN/AN/A-942.81%-93.82%8/12/2025 (Estimated)KMDAKamada$8.28M$0.2925.5422.340.979.92%6.30%4.49%8/13/2025 (Estimated)TBUFFTribute Pharmaceuticals CanadaN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest TBUFF, BNTC, HUMA, and KMDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q3 2025BNTCBenitec Biopharma-$0.36-$0.24+$0.12-$0.24N/AN/A5/14/2025Q1 2025KMDAKamada$0.07$0.07N/A$0.07$154.06 million$44.02 million5/13/2025Q1 2025HUMAHumacyte-$0.19-$0.10+$0.09$0.28$0.46 million$0.52 million3/28/2025Q4 2024HUMAHumacyte-$0.23-$0.16+$0.07-$0.16$0.64 million$7.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTCBenitec BiopharmaN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/AKMDAKamadaN/AN/AN/AN/AN/ATBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTCBenitec BiopharmaN/A25.4815.01HUMAHumacyteN/A1.101.10KMDAKamadaN/A4.842.73TBUFFTribute Pharmaceuticals CanadaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTCBenitec Biopharma52.19%HUMAHumacyte44.71%KMDAKamada20.38%TBUFFTribute Pharmaceuticals CanadaN/AInsider OwnershipCompanyInsider OwnershipBNTCBenitec Biopharma1.30%HUMAHumacyte5.10%KMDAKamada36.10%TBUFFTribute Pharmaceuticals CanadaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTCBenitec Biopharma2026.25 million23.15 millionNo DataHUMAHumacyte150155.12 million111.76 millionOptionableKMDAKamada36057.51 million36.73 millionOptionableTBUFFTribute Pharmaceuticals CanadaN/A113.72 millionN/ANot OptionableTBUFF, BNTC, HUMA, and KMDA HeadlinesRecent News About These CompaniesSimone Biles pays tribute to husband Jonathan Owens with tiny new tattooSeptember 21, 2024 | pagesix.comKid Rock's Toby Keith Tribute Concert Broke Taylor Swift's Audience Record?September 14, 2024 | snopes.comTRANSFORMERS ONE - Advance Screening & Prize Pack ContestSeptember 12, 2024 | tribute.caCate Blanchett Calls For Sustainability In Film Industry At TIFF Tribute Awards: “There Is A Moral Imperative To Make This Switch”September 11, 2024 | deadline.comInside the TIFF Tribute Awards: Angelina Jolie Asks for No Photographs and Viggo Mortensen Decries David Cronenberg’s Oscar SnubsSeptember 11, 2024 | variety.comTIFF 2024: Tragically Hip series honors beloved Canadian bandSeptember 6, 2024 | reuters.comTop country stars honor Toby Keith in a new special. Here's how to watchSeptember 2, 2024 | today.com‘Survivor’s Remorse’ actress Erica Ash dead at 46: Loni Love, Bow Wow and more pay tributeJuly 31, 2024 | pagesix.comValeo Pharma Inc. (VPHIF)May 17, 2024 | finance.yahoo.comAbout Tribute.caApril 1, 2024 | tribute.caMacGregor: A Remembrance Day tribute to Canada's Korean War veteransNovember 13, 2023 | ottawacitizen.comChurch Under Fire: Canada's War on Christianity - CastOctober 25, 2023 | tribute.caTerry Funk dies, aged 79: Pro wrestling industry pays tribute to hardcore iconAugust 27, 2023 | sportingnews.comRon Canada Biography & MoviesJuly 23, 2023 | tribute.caWhen her brother died, she wrote a moving tribute on a frisbee. Now, his memory is being shared from one city to the next.May 2, 2023 | yahoo.comAlberta tattoo artists pay tribute to laser removal expert who helped people move past traumaApril 29, 2023 | cbc.caMITSUBISHI TANABE PHARMA CANADA RECEIVES ENGAGEMENT LETTER FROM PAN-CANADIAN PHARMACEUTICAL ALLIANCE FOR RADICAVA® ORAL SUSPENSIONApril 27, 2023 | finance.yahoo.comHumboldt holds tribute five years after deadly bus crashApril 8, 2023 | thestar.comPaul O’Grady fans break down in tears over Lily Savage’s Blankety Blank tribute episode after shock deathApril 3, 2023 | thesun.co.ukGamer Crochets Destiny 2 Tribute to Zavalla Actor Lance ReddickApril 3, 2023 | gamerant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTBUFF, BNTC, HUMA, and KMDA Company DescriptionsBenitec Biopharma NASDAQ:BNTC$15.75 -0.73 (-4.43%) Closing price 04:00 PM EasternExtended Trading$16.34 +0.59 (+3.71%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Humacyte NASDAQ:HUMA$2.41 +0.04 (+1.69%) Closing price 04:00 PM EasternExtended Trading$2.39 -0.02 (-0.83%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Kamada NASDAQ:KMDA$7.15 +0.27 (+3.92%) Closing price 04:00 PM EasternExtended Trading$7.18 +0.03 (+0.49%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Tribute Pharmaceuticals Canada OTCMKTS:TBUFFTribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
